Design paper for CARDIO-TTRansform, a phase 3 placebo-controlled trial of eplontersen in transthyretin amyloid cardiomyopathy with 1432 randomised participants; primary end point is cardiovascular death and recurrent cardiovascular events through 140 weeks. No results yet.
RCTn = 1,432
Masri et al. Rationale and Design of CARDIO-TTRansform, a Phase 3 Trial of Eplontersen in Transthyretin Amyloid Cardiomyopathy